No. Switching patent counsel does not delay existing patent applications when handled properly. Your filings, priority dates, and USPTO deadlines remain intact. We coordinate the transition to ensure continuity—especially important for biotech and medical device companies working around development, clinical, or regulatory milestones.

No. Your existing patent applications stay in place. In most cases, the goal is to build on what has already been filed, not to redo it. We begin by reviewing your applications and identifying how best to strengthen or continue your strategy going forward.

Yes. We regularly take over prosecution and strategic planning for patents drafted by large national firms and boutiques alike. Our role is to understand the intent behind the filings and ensure they support your current technology and business objectives.

Your priority dates are preserved. Switching counsel does not affect your filing dates or ownership of your patent rights. For biotech and medical device companies, preserving early priority is often critical—and that protection remains unchanged.

No—provided the transition is handled with care. We are experienced in supporting biotech and medical device companies where patents intersect with regulatory planning. We focus on maintaining consistency and avoiding disruptions that could impact development or compliance.

Often, yes. Many small and growing companies switch counsel after realizing their IP spend has become unpredictable or disconnected from strategy. While quality patent work requires investment, a more focused approach can eliminate unnecessary filings and reduce long-term costs.

No. Our approach is collaborative and respectful. We start by understanding what has already been done and why. From there, we help you assess what is working, what may need adjustment, and how to move forward in a way that aligns with your goals.

Common transition points include:

• After one or two initial patent filings

• Before responding to a substantive USPTO office action

• Prior to a funding round or partnership discussion

• When patent costs begin to feel out of proportion to value

If you are unsure, an early review can help you decide whether switching makes sense now or later.

The process is straightforward. We:

1. Review your existing patent filings

2. Coordinate the transfer of representation

3. Align strategy with your current technology and business plans

4. Take over prosecution and future planning as needed

The transition is designed to be seamless and low-disruption.

Yes. It is very common for companies to begin with a large firm for initial filings and later transition to counsel that offers more strategic focus, accessibility, and cost transparency as the company grows.

If your company values:

• Clear communication

• Strategic guidance tied to business goals

• Experience with biotech and medical device technologies

• Predictable and transparent billing

then it is worth having a conversation.